logo-loader
Redx Pharma Plc

Redx Pharma's Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott after announcing they've sold one of their cancer research programmes for up to US$203mln.

The agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) has a tiered payment structure and will see Redx receive a upfront sum of US$3.5mln.

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £11.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Redx Pharma agrees US$203mln deal for cancer programme

Top stories from the Proactive Investors UK newsroom. Redx Pharma (LON:REDX) has agreed to sell its treatment for mutant tumours to US group Jazz Pharmaceuticals for US$3.5mln plus up to a further US$203mln in milestones. Jazz will be responsible for all future development, regulatory,...

on 10/7/19

2 min read